Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.
Sage Therapeutics looks to keep up momentum with SAGE-217 in bipolar depression, while Marinus tries to catch up with an oral postpartum depression project.